Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CBUS Stock Forecast 2026-2027
$3.91
Current Price
$256.27M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CBUS Price Targets
+539.4%
To High Target of $25.00
+309.2%
To Median Target of $16.00
-51.4%
To Low Target of $1.90
CBUS Price Momentum
+23.7%
1 Week Change
+70.0%
1 Month Change
+77.7%
1 Year Change
+124.7%
Year-to-Date Change
-6.7%
From 52W High of $4.19
+258.7%
From 52W Low of $1.09
📊 TOP ANALYST CALLS
Did CBUS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if UBS ETF is one of their latest high-conviction picks.
Latest CBUS Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CBUS has a bullish consensus with a median price target of $16.00 (ranging from $1.90 to $25.00). The overall analyst rating is N/A (N/A/10). Currently trading at $3.91, the median forecast implies a 309.2% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Amit Dayal at HC Wainwright & Co., projecting a 539.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CBUS Analyst Ratings
2
Buy
1
Hold
0
Sell
CBUS Price Target Range
Low
$1.90
Average
$16.00
High
$25.00
Current: $3.91
Latest CBUS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CBUS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 8, 2025 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $15.00 |
| May 12, 2025 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $17.50 |
| Mar 21, 2025 | HC Wainwright & Co. | Amit Dayal | Buy | Reiterates | $25.00 |
| Jan 22, 2025 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $18.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Amit Dayal | Buy | Reiterates | $25.00 |
| Oct 22, 2024 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $20.00 |
| Sep 24, 2024 | Alliance Global Partners | Matthew Venezia | Buy | Maintains | $23.50 |
| Sep 19, 2024 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $20.00 |
| Aug 12, 2024 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $21.00 |
| Jul 29, 2024 | Alliance Global Partners | Matthew Venezia | Buy | Initiates | $25.00 |
| Jul 19, 2024 | Canaccord Genuity | Austin Moeller | Buy | Assumes | $22.00 |
| May 10, 2024 | HC Wainwright & Co. | Amit Dayal | Buy | Reiterates | $25.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Amit Dayal | Buy | Maintains | $25.00 |
| Oct 9, 2023 | HC Wainwright & Co. | Amit Dayal | Buy | Reiterates | $25.00 |
Cibus Inc. (CBUS) Competitors
The following stocks are similar to UBS ETF based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cibus Inc. (CBUS) Financial Data
Cibus Inc. has a market capitalization of $256.27M with a P/E ratio of -0.3x. The company generates $3.79M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -63.1% quarter-over-quarter, while maintaining an operating margin of -2,510.2% and return on equity of -145.8%.
Valuation Metrics
Market Cap
$256.27M
Enterprise Value
$443.29M
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
69.7x
Growth & Margins
Revenue Growth (YoY)
-63.1%
Gross Margin
N/A
Operating Margin
-2,510.2%
Net Margin
0.0%
EPS Growth
-63.1%
Financial Health
Cash/Price Ratio
+11.6%
Current Ratio
1.3x
Debt/Equity
498.7x
ROE
-145.8%
ROA
-12.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cibus Inc. (CBUS) Business Model
About Cibus Inc.
What They Do
Develops sustainable agricultural solutions using gene-editing.
Business Model
Cibus Inc. generates revenue by developing and commercializing non-GMO crop varieties through its proprietary Rapid Trait Development System (RTDS). The company collaborates with seed companies and agricultural producers, offering innovative solutions that enhance crop traits, yield, and resilience, thereby addressing the global demand for sustainable agriculture.
Additional Information
Headquartered in San Diego, Cibus operates in the bioscience sector, focusing on food security and agricultural efficiency. Its advancements align with global environmental strategies, making it a key player in modern crop management and contributing to the evolving landscape of global food supply.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
157
CEO
Dr. Peter R. Beetham B.Sc., Ph.D.
Country
United States
IPO Year
2017
Website
www.cibus.comCibus Inc. (CBUS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Mission Produce, Inc. (AVO) Surpasses Q1 Earnings Estimates
Mission Produce (AVO) delivered earnings and revenue surprises of +42.86% and -7.90%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
Mar 12, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Cibus, Inc. (Nasdaq: CBUS) will report Q4 2025 financial results on March 17, 2026, with a conference call at 4:30 p.m. for investors.
Why It Matters
Cibus' upcoming earnings report could impact its stock performance, providing insights into financial health and growth in agricultural technology, crucial for assessing investment potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cibus will use its Rapid Trait Development System™ to develop resistance to Light Leaf Spot disease, which has caused yield losses of up to £300 million recently.
Why It Matters
Cibus's development of disease-resistant crops could significantly enhance agricultural yields, reducing losses and potentially increasing revenues, impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cibus, Inc. plans to offer shares of its Class A common stock in a public offering, with an option for underwriters to purchase an additional 15%. Interest from board members is noted but non-binding.
Why It Matters
Cibus plans to offer Class A shares, potentially diluting existing shareholder value. The interest from board members suggests confidence, but the offering's terms are uncertain.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cibus, Inc. (Nasdaq: CBUS) has priced a public offering of 13.33 million shares of Class A Common Stock at $1.50 per share, with board members purchasing 1 million shares.
Why It Matters
Cibus' public offering of shares at $1.50 each signals potential dilution for existing shareholders but also reflects insider confidence with board purchases, impacting stock sentiment and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cibus, Inc. and Interoc signed a non-binding LOI for potential 2027 market entry in Ecuador and Colombia, with plans for expansion into Peru, Central America, and the Caribbean for herbicide-tolerant rice traits.
Why It Matters
The LOI signals potential revenue growth for Cibus through market expansion in Latin America, enhancing investor confidence in future profitability and strategic partnerships.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A political agreement on New Genomic Techniques (NGTs) supports Cibus' plans to enhance plant breeding in Europe, potentially benefiting growers with improved traits.
Why It Matters
The political agreement on NGTs boosts Cibus' growth potential in Europe, likely enhancing its market position and attracting investor interest in biotech innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CBUS Stock
What is Cibus Inc.'s (CBUS) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Cibus Inc. (CBUS) has a median price target of $16.00. The highest price target is $25.00 and the lowest is $1.90.
Is CBUS stock a good investment in 2026?
According to current analyst ratings, CBUS has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CBUS stock?
Wall Street analysts predict CBUS stock could reach $16.00 in the next 12 months. This represents a 309.2% increase from the current price of $3.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cibus Inc.'s business model?
Cibus Inc. generates revenue by developing and commercializing non-GMO crop varieties through its proprietary Rapid Trait Development System (RTDS). The company collaborates with seed companies and agricultural producers, offering innovative solutions that enhance crop traits, yield, and resilience, thereby addressing the global demand for sustainable agriculture.
What is the highest forecasted price for CBUS Cibus Inc.?
The highest price target for CBUS is $25.00 from Amit Dayal at HC Wainwright & Co., which represents a 539.4% increase from the current price of $3.91.
What is the lowest forecasted price for CBUS Cibus Inc.?
The lowest price target for CBUS is $1.90 from at , which represents a -51.4% decrease from the current price of $3.91.
What is the overall CBUS consensus from analysts for Cibus Inc.?
The overall analyst consensus for CBUS is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are CBUS stock price projections?
Stock price projections, including those for Cibus Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 10:10 PM UTC